You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR JEMPERLI


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for JEMPERLI

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04926324 ↗ A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers Not yet recruiting GlaxoSmithKline Phase 1/Phase 2 2021-12-31 This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures.
NCT04926324 ↗ A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers Not yet recruiting Joseph Caster, Ph.D., M.D. Phase 1/Phase 2 2021-12-31 This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures.
NCT05526989 ↗ Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma Not yet recruiting GlaxoSmithKline Phase 2 2022-09-15 The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.
NCT05526989 ↗ Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma Not yet recruiting H. Lee Moffitt Cancer Center and Research Institute Phase 2 2022-09-15 The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.
NCT05870761 ↗ Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma Not yet recruiting Casey Cosgrove Phase 2 2023-06-30 This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent). Niraparib belongs to a class of drugs called PARP inhibitors that prevent cancer cells from growing. Dostarlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Dostarlimab belongs to a class of drugs called PD-1 inhibitors that uses the patient's own immune system to treat cancer (immuno-therapy). Giving niraparib and dostarlimab may work better in treating patients with uterine serous carcinoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for JEMPERLI

Condition Name

Condition Name for JEMPERLI
Intervention Trials
Penile Carcinoma 1
Rectal Neoplasm Malignant 1
Rectal Neoplasms 1
Recurrent Endometrial Serous Adenocarcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for JEMPERLI
Intervention Trials
Neoplasms 1
Recurrence 1
Cystadenocarcinoma, Serous 1
Penile Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for JEMPERLI

Trials by Country

Trials by Country for JEMPERLI
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for JEMPERLI
Location Trials
Ohio 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for JEMPERLI

Clinical Trial Phase

Clinical Trial Phase for JEMPERLI
Clinical Trial Phase Trials
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for JEMPERLI
Clinical Trial Phase Trials
Not yet recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for JEMPERLI

Sponsor Name

Sponsor Name for JEMPERLI
Sponsor Trials
GlaxoSmithKline 2
Joseph Caster, Ph.D., M.D. 1
H. Lee Moffitt Cancer Center and Research Institute 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for JEMPERLI
Sponsor Trials
Other 3
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.